 |
|
|
2012
|
| |
January
|
- Entered into agreement with Fox Chase Cancer Center to acquire clinical samples essential for the development and validation of companion diagnostic assays.
|
|
| |
March
|
- Formed a partnership with Biocare Medical to develop and commercialize an in vitro diagnostic immunohistochemical (IHC) kit to detect folate receptor alpha (FRalpha) expression in formalin fixed paraffin embedded (FFPE) malignant tissues. The kit will be available in the U.S. as a Class I IHC IVD assay and is CE marked for use in Europe.
- Completes enrollment of its 1100 patient Phase 3 pivotal trial FAR-131 in 1st relapsed platinum-sensitive ovarian cancer.
|
|
| |
April
|
- Morphotek Initiates Phase 2 Clinical Study of MORAb-004 in chemorefractory metastatic colorectal cancer.
|
|
| |
|
2011
|
| |
June
|
- Morphotek Initiates Phase 2 Clinical Study of Farletuzumab in First Line Non Small Cell Adenocarcinoma of the Lung
|
|
| |
May
|
- Morphotek Initiates Phase 2 Clinical Study of MORAb-004 in Metastatic Melanoma
|
|
| |
April
|
- Morphotek Announces Acquisition of Tumor Targeting Platform from Transmolecular Inc
- Morphotek Receives Beacon Award from Cancercare Patient Advocacy Group
- Morphotek Receives Additional Funding from the U.S. Department of Defense to Support Development of Therapeutic Antibodies to Combat Biowarfare Agents
|
|
| |
March
|
- Morphotek Signs Agreement with Biocare Medical to Develop and Commercialize a Diagnostic Kit for Folate Receptor Alpha Positive Malignant Tissues
|
|
2010
|
| |
November
|
- Initiates a Sponsored Research Agreement with Hokkaido University to Evaluate Amatuximab in Advanced Pancreatic Cancer
|
|
| |
October
|
- Morphotek Receives Funding from the U.S. Department of Defense to Support Development of Therapeutic Antibodies to Combat Microbial Bioweapons
|
|
| |
September
|
- Morphotek and Human Genome Sciences Select a Therapeutic Monoclonal Antibody to Advance into Development
|
|
| |
June
|
- Morphotek and Eisai Initiate MORAb-022 Clinical Study in Europe for the Treatment of Inflammatory Disease
|
|
| |
May
|
- Announces Appointment of Dr. Joye Bramble as Vice President of Pilot Plant Operations
|
|
| |
April
|
- Morphotek and Champions Biotechnology Announce an Agreement to Use Biomerk TumorgraftTM Platform to Evaluate Therapeutic Antibodies for Cancer
|
|
| |
March
|
- Morphotek Breaks Ground for A Pilot Plant to Manufacture Biological-based Drugs
|
|
| |
2009
|
|
| |
October
|
- Announces Licensing Deal with Centocor Ortho for Exclusive Rights to a Therapeutic Monoclonal Antibody
|
|
| |
September
|
- Awarded Funding from US Department of Defense to Develop Therapeutic Antibodies against Biowarfare Toxins
|
|
| |
August
|
- Announces Evaluation and Option Agreement with Cancer Innovations, Inc. for Therapeutic Monoclonal Antibodies
|
|
| |
July
|
- Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
|
|
| |
June
|
- Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, A Monoclonal Antibody for the Treatment of Cancer
|
|
| |
May
|
- Announces Manufacturing Services Agreement with Lonza Group LTD
|
|
| |
March
|
- Announces Collaboration with Human Genome Sciences to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
- Announces FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
- Announces Initiation of MORAb-009 Phase II Study in First-Line Treatment of Mesothelioma
|
|
| |
January
|
- Signs Collaboration with University Hospital Heidelberg to Develop Therapeutic Antibodies to Treat Cancer
|
|
|
2008
|
| |
December
|
- Signs Collaboration with University of Pennsylvania to Develop Antibodies to Targets Present in Hypoxic Regions of Tumors to Treat Cancer
|
|
| |
November
|
- Receives Funding from Department of Defense to Support Development of Therapeutic Antibodies to Treat Against Biowarfare Pathogens
|
|
| |
September
|
- Signs Agreement with Pivotal Biosciences to Access New Antibody Technology to Improve Therapeutic Activity
|
|
| |
August
|
- Opens Clinical Sites in Europe to Expand Ph2 trial of MORAb-009 in 1st line Pancreatic Cancer
- Signs Collaboration/License Agreement with the National Cancer Institute to Develop Antibodies to a Prostate Cancer Target
|
|
| |
July
|
- Morphotek Executive, Rodney Dausch, Named Small Company CFO of the Year in the Greater Philadelphia Region
|
|
| |
June
|
- Morphotek Receives Funding from Department of Defense to Develop Antibodies to Treat Against Infectious Disease Agents
|
|
| |
May
|
- Establishes Collaboration with the National Institute of Allergy and Infectious Diseases to Develop Therapeutic Antibodies to Treat Against Infectious Pathogens
|
|
| |
April
|
- Receive Orphan Status from European Regulatory Authorities for Farletuzumab in Ovarian Cancer and MORAb-009 in Pancreatic Cancer
|
|
| |
March
|
- Signs Agreement with Human Monoclonal International Inc to License and Develop an Antibody to Treat Cancer
|
|
| |
January
|
- Signs Collaboration Agreement with the Ludwig Institute to Validate Disease Targets
- Signs License Agreement with the National Cancer Institute to Develop Therapeutic Antibodies to Prostate Cancer Target
|
|
2007
|
| |
December
|
- Initiates MORAb-009 Randomized, Controlled Phase II Study in 1st Line Pancreatic Cancer
|
|
| |
October
|
- Morphotek Receives Funding From the National Institute of Allergy and Infectious Diseases to Develop Therapeutic Antibodies against Biowarfare Agents
|
|
| |
September
|
- Morphotek Receives Funding from the U.S. Department of Defense to Develop Therapeutic Antibodies against Biowarfare Agents
|
|
| |
June
|
- Morphotek CEO Nicholas Nicolaides Named Ernst & Young Entrepreneur Of The Year® 2007 Award Winner in Greater Philadelphia Region
|
|
| |
May
|
- Morphotek Signs Development and Clinical Supply Agreement with CMC Biopharmaceuticals A/S for Therapeutic Antibody to Treat Melanoma
|
|
| |
April
|
- Acquired by Eisai Corporation
|
|
| |
February
|
- Obtains Exclusive License from Micromet for Antibody to Treat Melanoma and Other Cancers
- President and CEO Nicholas Nicolaides honored as top 20 Scientist by R&D Directions
|
|
2006
|
| |
November
|
- Morphotek Selected as One of the Region's Top Three Fastest Growing Companies by Philadelphia 100®
|
|
| |
October
|
- Raised $40 Million to Advance its Antibody Pipeline
|
|
| |
June
|
- Initiation of Phase II Clinical Trial for MORAb-003 in Ovarian Cancer
|
|
| |
February
|
- FDA Accepts IND Application for MORAb-009
|
|
|
2005
|
| |
December
|
- Exclusive license agreement signed with the National Cancer Institute (MORAb-009)
|
|
| |
September
|
- Invitrogen Corporation Acquires Cell Line Optimization Service Business
|
|
| |
February
|
- FDA Accepts IND Application for MORAb-003
- Nicholas Nicolaides, Morphotek’s President & CEO was a “40 Under 40” honoree. The award is based on a recipients commitment to professional excellence and community involvement.
|
|
| |
January
|
- Development Grant Awarded by NCI
- Bioexecutive International magazine names Morphotek as “The Company to Watch”
|
|
2004
|
| |
December
|
- Exclusive License Agreement Signed with the Ludwig Institute for Cancer Research (MORAb-004)
|
|
| |
November
|
- Morphotek named “2004 Technology Company of the Year” by the Greater Philadelphia Chamber of Commerce. This award is based on a company’s achievements, vitality, creativity and impact on their industry.
|
|
| |
September
|
- CRADA signed with USAMRIID
|
|
| |
July
|
- Cross license agreement signed with Protein Design Labs
|
|
| |
March
|
- Morphotek was awarded the distinguished “Alumni Award” by the Ben Franklin Techonology Partenrs of Southeastern Pennsylvania
|
|
| |
February
|
- Series C Funding Raises $26 MM
|
|
|
2003
|
| |
October
|
- Manufacturing agreement singed with Baxter Healthcare
|
|
|
2002
|
| |
September
|
- PA Governor Mark Schweiker Awards Pennsylvania Opportunity Grant to Morphotek
|
|
| |
July
|
- Morphotek awarded US Army Grant
|
|
| |
May
|
- Morphotek Expands operations and Relocates to 41,000 sq. foot facility in Exton, PA
|
|
| |
April
|
- Research Agreement Signed with the Ludwig Institute for Cancer Research (MORAb-003)
|
|
| |
March
|
- Ben Franklin Technology Partners of Southeastern Pennsylvania names Morphotek the “Biotech Company of the Year”, recognizing their exceptional management team, prospects for achieving product, commercialization, and significant growth potential.
|
|
| |
February
|
- Research agreement Signed with the Wistar Institute
- Morphotek received the “People’s Choice” award at the annual Early Stage East Bio-Life-Tech Conferance
|
|
|
Back to Top
2001
|
| |
August
|
- Series B Funding Round raises $10MM
|
|
| |
February
|
- Ben Franklin Technology Partners of Southeastern Pennsylvnia awarded Morphotek the “Ben Franklin Emerging Fund” award
|
|
|
Back to Top
2000
|
| |
November
|
- Company’s Scientific Advisory Board Established
|
|
| |
July
|
- Company’s Board of Directors Established
|
|
| |
May
|
- Morphotek is founded by Drs. Luigi Grasso, Nicholas Nicolaides and Phillip Sass
|
|
| |
|
Back to Top
|
|